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Abstract
Background: The Golden Spike data set has been used to validate a number of methods for
summarizing Affymetrix data sets, sometimes with seemingly contradictory results. Much less use
has been made of this data set to evaluate differential expression methods. It has been suggested
that this data set should not be used for method comparison due to a number of inherent flaws.
Results: We have used this data set in a comparison of methods which is far more extensive than
any previous study. We outline six stages in the analysis pipeline where decisions need to be made,
and show how the results of these decisions can lead to the apparently contradictory results
previously found. We also show that, while flawed, this data set is still a useful tool for method
comparison, particularly for identifying combinations of summarization and differential expression
methods that are unlikely to perform well on real data sets. We describe a new benchmark,
AffyDEComp, that can be used for such a comparison.
Conclusion: We conclude with recommendations for preferred Affymetrix analysis tools, and for
the development of future spike-in data sets.
Background
The issue of method validation is of great importance to
the microarray community; arguably more important
than the development of new methods [1]. The microar-
ray analyst is faced with a seemingly endless choice of
methods, many of which give evidence to support their
claims of being superior to other approaches, which at
times can appear contradictory. Because of this, choice of
methods is often determined not by a rigorous compari-
son of method performance, but by what a researcher is
familiar with, what a researcher's colleagues have exper-
tise in, or what was used in a researcher's favorite paper.
Method validation is a difficult problem in microarray
analysis because, for the vast majority of microarray data
sets, we don't know what the "right answer" really is. For
example, in a typical analysis of differential gene expres-
sion, we rarely know which genes are truly differentially
expressed (DE) between different conditions. Perhaps
even worse than this, we rarely have any strong evidence
about the proportion of genes that are differentially
expressed.
Perhaps the most well-known and widely used bench-
mark for Affymetrix analysis methods is Affycomp [2].
This is essentially a benchmark for normalization and
summarization methods. While a very valuable tool of
method validation, Affycomp is not ideal for comparison
of DE methods because:
1. It uses data sets which only have a small number of DE
spike-in probesets.
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2. It only uses fold change (FC) as a metric for DE detec-
tion, and hence cannot be used to compare other compet-
ing DE methods.
More recently, the MicroArray Quality Control (MAQC)
study [3] has developed a large number of reference data
sets. The primary goal of this study was to show that
microarray results can be reproducible, however, a sec-
ondary goal was to provide tools for benchmarking meth-
ods. The study concluded that using FC as a DE method
gives results that are more reproducible than the other DE
methods studied. However, the study could not give rec-
ommendations about other important metrics for DE
methods such as sensitivity and specificity. The problem
here is that we don't know for sure which genes are differ-
entially expressed between the conditions. We could infer
this by comparing results across the different microarray
technologies used, but the different technologies may well
have similar biases, invalidating the results. We could also
infer which genes are differentially expressed by compari-
son with other technologies such as qRT-PCR, but again,
there could be similar biases in these technologies. Fur-
thermore, there are competing methods for detection of
DE genes using qRT-PCR, so we may well get contradic-
tory results when comparing different microarray DE
methods against different qRT-PCR DE methods.
The "Golden Spike" data set of Choe et al. [4] includes two
conditions; control (C) and sample (S), with 3 replicates
per condition. Each array has 14,010 probesets. 3,866 of
these probesets can be used to detect RNAs that have been
spiked in. 2,535 of these spike-in probesets relate to RNAs
that have been spiked-in at equal concentrations in the
two conditions. The remaining 1,331 probesets relate to
RNAs that have been spiked-in at higher concentrations in
the S condition relative to the C condition. As such, this
data set has a large number of probesets that are known to
be DE, and a large number that are known to be not DE.
This makes the Golden Spike data set potentially very val-
uable for validating DE methods.
There have been criticisms of the Golden Spike data set
from Dabney and Storey [5], Irizarry et al. [6] and Gaile
and Miecznikowski [7]. The main criticisms of [5] and [7]
center around the fact that the non-DE probesets in the
Golden Spike data set have non-uniform p-value distribu-
tions. This implies that any measure of significance of DE
will be incorrect. Significance measures are valuable
because they allow a researcher to make principled deci-
sions about how many genes might be DE, which is a goal
towards which we should strive. Unfortunately, we still
have no way of knowing for sure whether the non-uni-
form p-value distributions of the non-DE probesets seen
in the Golden Spike data set are particular to this data set,
or are a general feature of microarray data sets. Indeed, a
recent study by Fodor et al. [8] has suggested non-uniform
p-value distributions may be common. However, even if
we cannot reliably predict the proportion of genes that are
differentially expressed, we can still rank the genes from
most likely to be DE to least likely to be DE. In many
cases, a researcher might want a list of candidate genes
which will be investigated further. A common though
admittedly unprincipled approach is to choose the top N
candidate genes where N is determined by available
resources rather than statistical significance. In such situa-
tions it is the rank order of probability of being DE that is
used. The tool that has been used most extensively for
comparing methods on this data set is the receiver-opera-
tor characteristic (ROC) chart. The ROC chart only takes
into account the rank order of DE probesets, and hence is
not affected by concerns about non-uniform p-value dis-
tributions. Gaile and Miecznikowski [7] show that the
Golden Spike data set is not suitable for comparison of
methods of false discovery rate (FDR) control, but say
nothing about whether or not the data set can be used for
comparing methods of ranking genes by propensity to be
DE.
Irizarry et al. [6] detail three undesirable characteristics of
the Golden Spike data set induced by the experimental
design, and one artifact. The three undesirable character-
istics are:
1. Spike-in concentrations are unrealistically high.
2. DE spike-ins are all one-way (up-regulated).
3. Nominal concentrations and FC sizes are confounded.
While we agree that these are indeed undesirable charac-
teristics, and would recommend the creation of new
spike-in data sets that do not have these characteristics, we
do not believe that these completely invalidate the use of
the Golden Spike data set as a useful comparison tool.
Perhaps more serious is the artifact identified by Irizarry et
al. [6]. They show that the FCs of the spike-ins that are
spiked in at equal levels are lower than the "empty"
probesets (i.e. those not spiked in). Schuster et al. [9] have
recently suggested that this difference is due to differences
in non-specific binding, which in turn is due to differ-
ences in amounts of labeled cRNA between the C and S
conditions. We agree that this artifact invalidates compar-
ison methods that use the set of all unchanging (equal FC
and empty) probesets as true negatives when creating
ROC charts. However, we argue that we can still use the
Golden Spike data set as a valid benchmark by using ROC
charts with just the equal FC probesets as our true nega-
tives (i.e. by ignoring the empty probesets).BMC Bioinformatics 2008, 9:164 http://www.biomedcentral.com/1471-2105/9/164
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The Golden Spike data set has been used to validate many
different methods for summarizing Affymetrix data sets.
Choe et al. [4] originally used this data set to show that a
modified form of MAS5.0 (which we will refer to as CP for
Choe Preferred) outperforms RMA [10], GCRMA [11] and
MBEI (the algorithm used in the dChip software) [12]. Liu
et al. [13] used the data set to show that multi-mgMOS
[14] can outperform CP. Hochreiter et al. [15] used the
data set to show that FARMS outperforms RMA, MAS5.0
and MBEI, and that RMA outperforms MAS5.0 and MBEI,
in apparent contradiction to Choe et al. [4]. Chen et al.
[16] used the data to show that DFW and GCRMA outper-
form RMA, MAS5.0, MBEI, PLIER [17], FARMS and CP,
again in apparent contradiction to Choe et al. [4]. All of
these papers used some form of ROC curve in their analy-
ses. The confusing, and seemingly contradictory results,
make it difficult for typical Affymetrix users to decide
between methods.
The reason for the differing results arise from the different
choices made at various stages of the analysis pipeline. In
particular, different DE methods have been used in the
papers cited above. Only Choe et al. [4] and Liu et al. [13]
have compared different DE methods on the results of the
same normalization and summarization methods.
Choices for DE methods include: fold change (FC); t-tests;
modified t-tests such as those used by limma [18] and
Cyber-T [19]; and the probability of positive log ratio
(PPLR) method [13]. In addition to choice of DE method,
there are choices to be made at other stages of the analysis
pipeline. We broadly summarize these as the following six
choices, each of which can have a significant influence
over results:
1. Summary statistic used (e.g. RMA, GCRMA, MAS5.0,
etc.). Note that Choe et al. [4] broke this particular choice
down to four separate sub-choices of methods for back-
ground correction, probe-level normalization, PM adjust-
ment, and expression summary.
2. Post-summarization normalization method. Choe et al.
[4] compared no further normalization against the use of
a loess probeset-level normalization based on the known
invariant probesets.
3. Differential expression (DE) method. Choe et al. [4]
compared t-test, Cyber-T [19] and SAM [20].
4. Direction of differential expression. Choe et al. [4] used
a 2-sided test (as opposed to, for example, a 1-sided test of
up-regulation).
5. Choice of true positives. Choe et al. [4] used all spike-in
probesets with fold-change (FC) greater than 1.
6. Choice of true negatives. Choe et al. [4] used all invari-
ant probesets. This included both probesets that were
spiked in at equal quantities, as well as the so-called
"empty" probesets.
Table 1 shows the choices we believe were made in vari-
ous studies of the Golden Spike data set. In addition to the
studies identified in Table 1, Lemieux [21] and Hess and
Iyer [22] report results of "probe-level" methods for
detecting differential expression. We do not consider
these approaches here. In addition to the choices at the six
steps of the analysis pipeline highlighted above, there are
choices to be made about how the data are displayed, and
what metrics should be used for comparison. There are
Table 1: Analysis choices of various studies of the "Golden Spike" data set. These are choices we believe were made for each of the six 
stages of the analysis pipeline we have outlined.
Study Summarization 
method
Post-summ 
Normalization
DE method Dir True positives True negatives
Choe et al. [4] CP, MAS5.0, RMA, 
GCRMA, MBEI 
plus many variants 
of these
none, 
loess_invariant
t-test, Cyber-T, 
SAM
either FC >1 invariant
Liu et al. [13] CP, multi-mgMOS loess_invariant Cyber-T, PPLR up FC >1 invariant
Hochreiter et al. 
[15]
MAS5.0, RMA, 
MBEI and FARMS
none SAM up FC >1 invariant
Chen et al. [16] CP, MAS5.0, RMA, 
GCRMA, MBEI, 
PLIER, FARMS and 
DFW
none FC either FC >1 and FC = 
x(for all x)
invariant
Current study CP, MAS5.0, RMA, 
GCRMA, MBEI, 
multi-mgMOS, 
FARMS, DFW, 
PLIER
none, 
loess_invariant, 
loess_equal, 
loess_all
FC, t-test, Cyber-
T, limma and PPLR
either, up and 
down
FC >1, low FC, 
medium FC, high 
FC and FC = x(for 
all x)
equal and invariantBMC Bioinformatics 2008, 9:164 http://www.biomedcentral.com/1471-2105/9/164
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many types of "ROC-like" charts that can be created. An
ROC chart is generally considered to be one where the x-
axis shows the false-positive rate (FPR), and the y-axis the
true-positive rate (TPR). This type of chart is used in the
Liu et al. [13], Hochreiter et al. [15] and Chen et al. [16]
papers. Another type of ROC curve has the false-discovery
rate (FDR) along the x-axis. This type of ROC curve was
used in the original Choe et al. paper [4]. There are a large
range of other types of chart for visualizing classifier per-
formance [23] that we have not considered. In addition,
choices need to be made about whether to show the full
ROC charts (with x- and y-axes both between 0 and 1), or
whether to just display a part of the chart. While using the
full ROC chart is the only way of assessing the perform-
ance of a method across the full range of data, this can
result in charts where the lines of each method are very
close together and hence difficult to distinguish. Often, an
analyst is most interested in methods which will give the
least number of false positives for a relatively small
number of true positives, as only a small number of genes
will be investigated further. In such cases it can often be
informative to show the ROC chart for a much smaller
range of FPRs, for example, between 0 and 0.05. The
charts in the original Choe et al. paper [4] use different x-
axis cutoffs to show different aspects of the analysis.
The most commonly used metric for assessing a DE detec-
tion method's performance is the Area Under the standard
ROC Curve (AUC). This is typically calculated for the full
ROC chart (i.e. FPR values from 0 to 1), but can also be
calculated for a small portion of the chart (e.g. FPRs
between 0 and 0.05). Other metrics that might be used are
the number or proportion of true positives for a fixed
number or proportion of false positives, or conversely the
number or proportion of false positives for a fixed
number or proportion of true positives.
In this study we have analyzed all combinations of the
various options shown in the last row of Table 1. In addi-
tion, we have created charts displaying the data in differ-
ent ways. In the next section we show how results can vary
when making different choices at the stages of the analysis
pipeline highlighted above. We also discuss what we
believe are good choices. We detail a web resource called
AffyDEComp which can be used as a limited benchmark
for DE methods on Affymetrix data. We also highlight
some issues of reproducibility in comparative studies. We
conclude by making recommendations on choices of
Affymetrix analysis methods, and desired characteristics
of future spike-in data sets.
Results and Discussion
Direction of Differential Expression
We can see from Table 1 that studies to date have used
either a 1-sided test or a 2-sided test for differential expres-
sion. A potential problem with using a 2-sided test on this
data set becomes apparent if we compare the tests using
the other analysis choices of Chen et al. [16]. Figure 1
shows the ROC charts created using a 2-sided test of dif-
ferential expression, and 1-sided tests of up- and down-
regulation. This was created using just those probesets
that have a FC of 1.2 as true positives. Figure 1a is the
equivalent of Figure 3 of Chen et al. [16]. This appears to
show that DFW has the strongest performance. However,
Comparison of 1- and 2-sided tests of DE for very low FC genes Figure 1
Comparison of 1- and 2-sided tests of DE for very low FC genes. ROC charts of Golden Spike data using a 2-sided and 
two 1-sided tests of DE. For these charts all unchanging probesets are used as true negatives, genes with FC of 1.2 are used as 
true positives, and no post-summarization normalization is used. We only show results for the FC DE detection method. The 
different charts show a.) probesets selected using a 2-sided test of DE, b.) probesets selected using a 1-sided test of up-regula-
tion and c.) probesets selected using a 1-sided test of down-regulation. The diagonal line shows the "line of no-discrimination". 
This shows how well we would expect random guessing of class labels to perform.
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if we look at Figure 1b and Figure 1c we see that the meth-
ods that appear to be performing strongly in Figure 1a are
actually mainly detecting down-regulated genes. The rea-
son for this becomes clear when we look at Figure 2 from
Irizarry et al. [6]. There we see that spike-in genes with
small fold changes greater than 1, actually have M values
(i.e. fold changes) generally less than the M values of the
"empty probesets" which form the majority of the nega-
tives from which this chart was created.
The choice of whether 1-sided or 2-sided tests should be
used for comparison of methods is debatable. A 1-sided
test for down-regulation is clearly not a sensible choice
given that all the known DE genes are up-regulated. We
would expect a 1-sided test of up-regulation to give the
strongest results, given that all the unequal spike-ins are
up-regulated. However, in most real microarray data sets,
we are likely to be interested in genes which show the
highest likelihood of being DE, regardless of the direction
of change. As such, we will continue to use both a 2-sided
test, and a 1-sided test of up-regulation in the remainder
of the paper. In our comprehensive analysis, however, we
also include results for 1-sided tests of down-regulation
for completeness.
True negatives
Figure 2 shows the ROC charts created using the same
choices as used in Figure 1, except that this time we use
just the probesets which have been spiked in at equal con-
centrations as our true negatives. Here we see a very differ-
ent picture. Firstly, the differences between different
summarization methods are less pronounced when using
a 2-sided test of DE. Also, the charts for detecting up- and
down-regulated genes are quite similar. This indicates that
it is actually very difficult for methods to distinguish these
two classes. This is perhaps not surprising given the simi-
larities in the fold changes (the true negatives have a FC of
1 and the true positives have a FC of 1.2). We should note,
however, that the ROC curves detecting up-regulation
(Figure 2b) are generally slightly above the diagonal (i.e.
slightly better than random guessing), whereas the ROC
curves detecting down-regulation (Figure 2c) are generally
slightly below the diagonal (i.e. slightly worse than ran-
dom guessing). This gives us confidence that by just using
equal-valued spike-ins as our true negatives, our ROC
curves can detect genuine improvements in detecting DE
genes due to different methods.
Irizarry et al. [6] showed that the FCs of the equal concen-
tration spike-ins are quite different from those of the
empty probesets. Another difference between these two
sets of probesets is in their intensities. Figure 3 shows den-
sity plots of the intensities of the equal and empty
probesets. Figure 3 also shows density plots of intensities
of unchanging (i.e. equal or empty) probesets, and of the
true positives (spike-ins with FC > 1). The first thing to
note is that the plots for empty and unchanging probesets
are very similar. This is to be expected as there are many
more empty probesets than equal probesets. We also see
that, although there are differences between the equal and
TP plots (the confounding between concentration and FC
identified by Irizarry et al. [6]), these are not nearly so pro-
nounced as the differences between the unchanging and
TP plots. Indeed, from Figure 3 we can see that a classifier
Comparison of 1- and 2-sided tests using only equal spike-ins as true negatives Figure 2
Comparison of 1- and 2-sided tests using only equal spike-ins as true negatives. ROC charts of Golden Spike data 
using a 2-sided and two 1-sided tests of DE, with only the equal spike-ins used as true negatives. Genes with FC of 1.2 are used 
as true positives, and no post-summarization normalization is used. We only show results for the FC DE detection method. 
The legend is the same as in Figure 1. The different charts show a.) probesets selected using a 2-sided test of DE, b.) probesets 
selected using a 1-sided test of up-regulation and c.) probesets selected using a 1-sided test of down-regulation. As with Figure 
1, we include lines of no-discrimination.
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(b) 1−sided test of down−regulation
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based purely on intensity alone would separate well the
unchanging probesets from the TPs. This fact, together
with the artifact identified by Irizarry et al. [6], leads us to
recommend using only the equal concentration spike-ins
as the set of true negatives for method comparison. In our
comprehensive analysis, however, we also include results
when using all the unchanging probesets, for complete-
ness.
Post-Summarization Normalization
Thus far, we have not considered the effect of post-sum-
marization normalization, which was shown by Choe et
al. [4] to have a significant effect on results. Figure 4 shows
the effect of such normalizations. Note that unlike Figures
1 and 2 we are here treating all of the spike-ins with FC >
1 as our true positives, not just those with FC = 1.2. Here
we can see that post-summarization loess normalization
improves results, which is consistent with the results of
Choe et al. [4]. Furthermore, we see that post-summariza-
tion normalization using just the equal-valued spike-ins
improves results to a greater extent than using a loess nor-
malization based on all probesets.
We agree with Gaile and Miecznikowski [7] that "the
invariant set of genes used for the pre-processing steps in
Choe  et al. should not have included the empty null
probesets". As such, for the remainder of this paper will
we not use the empty probesets in loess normalization. In
our comprehensive analysis we also include, for com-
pleteness, results when using all of the following post-
summarization normalization strategies: no post-summa-
rization normalization, a loess normalization based on all
spike-in probesets, a loess normalization based on all the
unchanging probesets and a loess normalization based on
the equal-valued spike-ins.
Differential Expression Detection Methods
We turn now to the issue of DE detection methods. Figure
5 shows ROC charts created with different combinations
of summarization and DE methods. Different colors are
Density plots of intensities for different choices of true negatives Figure 3
Density plots of intensities for different choices of true negatives. These plots show the distributions of intensities of 
perfect match (PM) probes across all six arrays of the Golden Spike data, for different subsets of probesets. We show plots for 
three potential choices of true negative (TN) probesets: the Empty probesets are defined as those for which there is no corre-
sponding spike-in RNAs. The Equal probesets are defined as those spiked in at equal concentrations in the C and S conditions. 
The Unchanging probesets are defined as the set of all Empty and Equal probesets. For this chart we have defined true positives 
(TP) as those probesets which have been spiked in at higher concentration in the S condition relative to the C condition.
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Comparison of different post-summarization normalization strategies Figure 4
Comparison of different post-summarization normalization strategies. ROC charts of Golden Spike data using a 2-
sided and a 1-sided test of DE, and using three different post-summarization normalization strategies. For these charts only the 
equal spike-ins are used as true negatives, and all spike-ins with FC > 1 are used as true positives. We only show results for the 
FC DE detection method. The top row relates to data sets created without any post-summarization normalization. The middle 
row relates to data sets created using all probesets for the loess normalization. The bottom row relates to data sets created 
using only the equal spike-in probesets for the loess normalization. The left column shows probesets selected using a 2-sided 
test of DE. The right column shows probesets selected using a 1-sided test of up-regulation.
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used to identify different DE methods, and different line
types are used to identify different summarization meth-
ods. Tables 2 and 3 show the AUCs of the ROC charts of
Figure 5, with the top 10 performing combinations of
summarization and DE detection methods shown in
bold. Of the DE methods, Cyber-T appears to have partic-
ularly good performance, with 5 of the top 10 AUCs when
using a 2-sided test, and 4 of the top 10 AUCs when look-
ing specifically for up-regulation. Of the other DE meth-
ods, limma is the only method to have more than 1 AUC
in the top 10 for both 2-sided and 1-sided tests. Looking
at the summarization methods, multi-mgMOS has 4
AUCs in the top 10 for both 2-sided and 1-sided tests,
while both CP and GCRMA have 2 AUCs in the top 10 for
both tests. The top AUC in both 2-sided and 1-sided tests
is obtained using multi-mgMOS and PPLR.
The end goal of an analysis is often to identify a small
number of genes for further analysis. As such, we might be
interested not in how well a method performs on the
whole of a data set, but specifically in how well it per-
forms in identifying those genes determined to be most
likely to be DE. As such we are particularly interested in
the ROC chart at the lowest values of FPR. Figure 6 shows
the same ROC curves as Figure 5b up to FPR values of
0.04. From Figure 6 we can see that, although the combi-
nation of multi-mgMOS and PPLR has the highest overall
AUC, this method does not have the strongest perform-
ance for most values of FPR between 0 and 0.04. For FPR
values between about 0.005 and 0.03, the combination of
CP and Cyber-T has the strongest performance. For even
lower FPR values, both FARMS and DFW in combination
with FC are the strongest performers for small ranges of
FPR.
Figure 6 can be used for overall comparisons of DE meth-
ods. In general, we see that Cyber-T tends to outperform
limma, and both of these methods generally outperform
the use of standard t-tests. The performance of FC as a DE
detection method varies much more, depending on the
summarization method used. When FC is used in combi-
nation with DFW, FARMS or GCRMA, performance is gen-
erally amongst the best. However, performance of FC with
RMA, MBEI and PLIER is less strong, and the combination
of FC with multi-mgMOS, MAS5.0 or CP is particularly
poor. Of the summarization methods that perform well
with FC, FARMS and DFW have generally poor perform-
ance when used in combination with other methods.
GCRMA has reasonable performance in combination
with Cyber-T, but is in the lower half of summarization
Comparison of combinations of summarization/DE detection methods Figure 5
Comparison of combinations of summarization/DE detection methods. ROC charts of Golden Spike data using a 2-
sided and a 1-sided test of DE, using different combinations of summarization and DE detection methods. For these charts only 
the equal spike-ins are used as true negatives, and all spike-ins with FC > 1 are used as true positives. A post-summarization 
loess normalization based on the equal-valued spike-ins was used. The different charts show a.) probesets selected using a 2-
sided test of DE, and b.) probesets selected using a 1-sided test of up-regulation. The two legends refer to both a.) and b.)
2−sided DE test
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methods when used in combination with either limma or
standard t-tests.
True positives
So far we have used all of the genes that are spiked-in at
higher concentrations in the S samples relative to the C
samples as our true positives. This is perhaps the best and
fairest way to determine overall performance of a DE
detection method. However, we might also be interested
in whether certain methods perform particularly well in
"easier" or "more difficult" cases. Indeed, many analysts
are only interested in genes which are determined not
only to have a probability of being DE that is significant,
but also have a FC which is greater than some pre-deter-
mined threshold. In order to determine which methods
perform more strongly in "easy" or "difficult" cases, we
can restrict our true positives to just those genes than are
known to be DE by just a small FC, or to those that are
very highly DE.
Figure 7 shows AUC values where the true positives are a
subset of all the DE genes. The subsets are determined by
the known FCs. The first thing to note from Figure 7 is that
methods generally perform much better at detecting high
FC genes, than they do in detecting low FC genes. This is
to be expected of course. From Figure 7 we can also see
that methods that perform well overall tend to also per-
form well regardless of whether the FCs are low, medium
or high. There are, nonetheless, differences in the ranking
of methods in each case. For example, although the com-
bination of multi-mgMOS and PPLR was shown to have
the highest AUC overall, it is outperformed by the combi-
nation of RMA and FC when considering either medium
or high FC genes as true positives. Conversely, RMA/FC is
outperformed by many other summarization/DE detec-
tion combinations for low FC genes. These results show us
that the performance of a method may depend on the bal-
ance of easy and difficult cases.
Comprehensive Analysis
We have created ROC charts for each combination of
analysis choices from the final row of Table 1. For each of
these combinations we have created ROC charts where the
x-axis shows FPR, and where the x-axis shows FDR. We
have also created charts where FPR/FDR has the full range
of 0 to 1, and where FPR/FDR has the range 0 to 0.05. We
have created a web resource called AffyDEComp [24]
where ROC charts can be displayed by specifying the anal-
ysis pipeline choices. In addition, AUC charts similar to
Figure 7 are also shown for different combinations of
analysis pipeline choices. AffyDEComp also includes a
table of thirteen key performance metrics for each combi-
nation of summarization and DE detection methods. The
metrics used are:
1. AUC where equal-valued spike-ins are used as true neg-
atives, spike-ins with FC > 1 are used as true positives, a
post-summarization loess normalization based on the
equal-valued spike-ins is used, and a 1-sided test of up-
regulation is the DE metric. This gives the values shown in
Table 3.
2. as 1. but using a 2-sided test of DE. This gives the values
shown in Table 2.
3. as 1. but with low FC spike-ins used as true positives.
This gives the values shown in Figure 7.
4. as 1. but with medium FC spike-ins used as true posi-
tives. This gives the values shown in Figure 7.
Table 2: AUCs for 2-sided test of DE. This table shows AUC 
values for different combinations of summarization and DE 
detection methods. The 10 highest AUC values are highlighted 
in bold. Note that the PPLR method is only applicable to 
summarization methods that give uncertainty estimates as well 
as mean expression levels for each probeset. These results were 
calculated using only the equal spike-ins as true negatives, and all 
spike-ins with FC > 1 as true positives. A post-summarization 
loess normalization using the equal-valued spike-ins was used. 
The results in this table are for 2-sided tests of DE.
limma FC t-test Cyber-T PPLR
mmgMOS 0.903 0.861 0.902 0.919 0.922
MAS5 0.884 0.848 0.879 0.905
CP 0.905 0.873 0.898 0.919 0.889
PLIER 0.898 0.889 0.889 0.911
RMA 0.881 0.885 0.858 0.886 0.860
GCRMA 0.890 0.902 0.883 0.909
DFW 0.764 0.815 0.732 0.703 0.806
MBEI 0.885 0.884 0.870 0.897 0.855
FARMS 0.842 0.891 0.805 0.844 0.772
Table 3: AUCs for 1-sided test of up-regulation. This table shows 
AUC values for different combinations of summarization and DE 
detection methods. The 10 highest AUC values are highlighted 
in bold. Note that the PPLR method is only applicable to 
summarization methods that give uncertainty estimates as well 
as mean expression levels for each probeset. These results were 
calculated using only the equal spike-ins as true negatives, and all 
spike-ins with FC > 1 as true positives. A post-summarization 
loess normalization using the equal-valued spike-ins was used. 
The results in this table are for 1-sided tests of up-regulation.
limma FC t-test Cyber-T PPLR
mmgMOS 0.940 0.920 0.938 0.949 0.951
MAS5 0.924 0.908 0.921 0.934
CP 0.940 0.928 0.935 0.948 0.932
PLIER 0.934 0.929 0.930 0.941
RMA 0.929 0.932 0.914 0.932 0.917
GCRMA 0.926 0.946 0.921 0.944
DFW 0.817 0.918 0.794 0.830 0.912
MBEI 0.928 0.928 0.920 0.934 0.915
FARMS 0.883 0.938 0.847 0.908 0.893BMC Bioinformatics 2008, 9:164 http://www.biomedcentral.com/1471-2105/9/164
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5. as 1. but with high FC spike-ins used as true positives.
This gives the values shown in Figure 7.
6. as 1. but with all unchanging probesets used as true neg-
atives.
7. as 1. but with all unchanging probesets used as true neg-
atives, and a post-summarization loess normalization
based on the unchanging probesets.
8. as 1. but with a post-summarization loess normaliza-
tion based on all spike-in probesets.
9. as 1. but with a no post-summarization normalization.
10. as 1. but giving the AUC for FPRs up to 0.01.
11. the proportion of true positives without any false pos-
itives (i.e. the TPR for a FPR of 0), using the same condi-
tions as 1.
12. the TPR for a FPR of 0.5, using the same conditions as
1.
13. the FPR for a TPR of 0.5, using the same conditions as
1.
We are happy to include other methods if they are made
available through Bioconductor packages. We also intend
to extend AffyDEComp to include future spike-in data sets
as they become available. In this way we expect this web
resource to become a valuable tool in comparing the per-
formance of both summarization and DE detection meth-
ods.
Comparison of combinations of summarization/DE detection methods at low false positive rates Figure 6
Comparison of combinations of summarization/DE detection methods at low false positive rates. ROC charts of 
Golden Spike data using a 1-sided test of DE, using different combinations of summarization and DE detection methods, and 
showing only false positive rates between 0 and 0.04, and false negative rates between 0.5 and 0.9. For these charts only the 
equal spike-ins are used as true negatives, and all spike-ins with FC > 1 are used as true positives. A post-summarization loess 
normalization based on the equal-valued spike-ins was used. The legend is the same as in Figure 5.
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Reproducible Research
One of the main problems with comparing different anal-
yses of the same data sets is knowing exactly what code
has been used to create results. As an example, the loess
normalization used in a number of the papers shown in
Table 1 has a "span" parameter. None of the papers men-
tion what value has been used for this parameter, though
Choe et al. [4] have made all their source code available,
albeit on their website rather than as supplementary infor-
mation to their paper. We believe that the only way to pro-
vide analysis results that are reproducible is to either:
1. provide full details of all parameter choices used in the
papers Methods section, or
2. make the code used to create the results available, ide-
ally as supplementary information to ensure a permanent
record.
We recommend that journals should not accept method
comparison papers unless either of these is done. This
paper was prepared as a "Sweave" document [25]. The
source code for this document is a mixture of LaTeX and R
code. We have made the source code available as Addi-
tional file 1. This means that all the code used to create all
the results in this paper, and in AffyDEComp [24], are
available and all results can be recreated using open
source tools.
Conclusion
We have performed the most comprehensive analysis to
date of the Golden Spike data set. In doing so we have
identified six stages in the analysis pipeline where choices
need to be made. We have made firm recommendations
about the choices that should be made for just one of
these stages if using the Golden Spike data for comparison
of summarization and DE expression detection methods
using ROC curves: we recommend that only the probesets
Comparison of different choices of true positives Figure 7
Comparison of different choices of true positives. Areas under ROC curves of Golden Spike data using different combi-
nations of summarization and DE detection methods, and different sets of true positives. For these charts only the equal spike-
ins are used as true negatives. The chart shows probesets selected using a 1-sided test of up-regulation. The Low true positives 
are those spike-ins with a FC greater than 1 but less than or equal to 1.7. The Medium true positives are those spike-ins with a 
FC between 2 and 2.5 inclusive. The High true positives are those spike-ins with a FC greater than or equal to 3. The y-axis 
shows -log(1-AUC) rather than AUC, as this gives a better separation between the higher AUC values, but retains the same 
rank order of methods. The x-axis is categorical, with points jittered to avoid placement on top of each other.
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that have been spiked-in should be used as the true nega-
tives for the ROC curves. By doing this we overcome the
problems due to the artifact identified by Irizarry et al. [6].
We would also recommend the following choices:
1. The use of a post-summarization loess normalization,
with the equal spike-in probesets used as the subset to
normalize with. This is also recommended by Gaile and
Miecznikowski [7].
2. The use of a 1-sided test for up-regulation of genes
between the C and S conditions. This mimics the actual
situation because all the non-equal spike-ins are up-regu-
lated.
3. The use of all up-regulated probesets as the true posi-
tives for the ROC chart.
Using the above recommendations, we created ROC
charts for all combinations of summarization and DE
methods (Figure 5b and Table 3). This showed us that
there was no clear DE detection method that stood out,
but that what is important is the combination of summa-
rization and DE method. We saw that the combination of
multi-mgMOS and PPLR gave the largest AUC. One of the
downsides with the PPLR approach is that there is no prin-
cipled way of determining the proportion of genes that are
DE, as is claimed by some FDR methods. Other combina-
tions that had strong performance included GCRMA/FC,
and Cyber-T used in conjunction with various normaliza-
tion methods. By looking at very small FPRs (Figure 6),
CP/Cyber-T, FARMS/FC and DFW/FC were all shown to
be potentially valuable when identifying a small number
of potential targets. If looking only for genes with larger
FCs (Figure 7), RMA/FC was seen to give the strongest per-
formance.
It should be noted that the design of this experiment
could favor certain methods. We have seen that the inten-
sities of the spike-in probesets are particularly high. Esti-
mates of expression levels are known to be more accurate
for high intensity probesets. This could favor the FC
method of determining DE.
Furthermore, the replicates in the Golden Spike study are
technical rather than biological, and hence the variability
between arrays might be expected to be lower in this data
set than in a typical data set. Again, this might favor the FC
DE method.
We agree with Irizarry et al. [6] that the Golden Spike data
set is flawed. In particular, we recognize that in creating
ROC charts from just those probesets which were spiked-
in, we are using a data set where the probe intensities are
higher than in many typical microarray data sets. Also,
applying a post-summarization normalization is not
something that many typical analysts will perform, but is
believed to be necessary to overcome some of the limita-
tions of this data set, namely that the experiment is unbal-
anced due to the fact that all the DE spike-ins are up-
regulated. We believe that using only the equal-valued
spike-in probesets, both as true negatives and for the post-
summarization normalization, is the most appropriate
way of analyzing this particular data set. Furthermore,
given the issues highlighted in the introduction regarding
Affycomp and comparisons with qRT-PCR results, we
believe that the Golden Spike data set is still the most
appropriate tool for comparing DE methods. To this end
we have created the AffyDEComp benchmark to enable
researchers to compare DE methods. However, we should
stress that we are not, at this stage, recommending that
AffyDEComp be used as a reliable benchmark as the
Golden Spike data set might not be representative of data
sets more generally. In particular, just because a method
does well here, doesn't necessarily mean that the method
will do well generally. At this time, AffyDEComp might
better be suited to identifying combinations of summari-
zation and DE detection methods that perform particu-
larly poorly.
We encourage the community to develop further spike-in
data sets with large numbers of DE probesets. In particu-
lar, we encourage the generation of data sets where:
1. Spike-in concentrations are realistic
2. DE spike-ins are a mixture of up- and down-regulated
3. Nominal concentrations and FC sizes are not con-
founded
4. The number of arrays used is large enough to be repre-
sentative of some of the larger studies being performed
today
We believe that only by creating such data sets will we be
able to ascertain whether the artifact noted by Irizarry et al.
[6] is a peculiarity of the Golden Spike data set, or is a gen-
eral feature of spike-in data sets. More importantly, the
creation of such data sets should improve the AffyDE-
Comp benchmark, and hence enable the community to
better evaluate DE detection methods for Affymetrix data.
Methods
The raw data from the Choe et al. [4] study was originally
downloaded from the author's website [26]. All analysis
was carried out using the R language (version 2.6.0).
MAS5.0, CP, RMA and MBEI expression measures were
created using the Bioconductor [27] affy package (version
1.16.0). GCRMA expression measures were created usingBMC Bioinformatics 2008, 9:164 http://www.biomedcentral.com/1471-2105/9/164
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the Bioconductor gcrma package (version 2.10.0). PLIER
expression measures were created using the Bioconductor
plier  package (version 1.8.0). multi-mgMOS expression
measures were created using the Bioconductor puma pack-
age (version 1.4.1). FARMS expression measures were cre-
ated using the FARMS package (version 1.1.1) from the
author's website [28]. DFW expression measures were cre-
ated using the affy package and code from the author's
website [29]. Cyber-T results and Loess normalization
were obtained using the goldenspike package (version 0.4)
[26]. All other analysis was carried out using the Biocon-
ductor puma package (version 1.4.1).
The code used to create all results in this document is
included as Additional file 1.
List of abbreviations
DE – differentially expressed or differential expression, as
appropriate. FC – fold change. MAQC -MicroArray Qual-
ity Control. ROC – receiver-operator characteristic. FPR –
false-positive rate. TPR -true-positive rate. FDR – false-dis-
covery rate. AUC – area under curve (in this paper this
refers to the area under the ROC curve).
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